Table 1.
R : Sa
ratio |
MSC-BM | MSC-BM IFN-γ/TNF-α |
Os-MSC-BM | Os-MSC-BM IFN-γ/TNF-α |
---|---|---|---|---|
1 : 0.5 | 4.3 ± 2.1b | 1.1 ± 0.3 | 3.3 ± 0.3 | 1.7 ± 0.2 |
1 : 0.25 | 4.5 ± 1.4 | 1.0 ± 0.3 | 3.1 ± 0.1 | 1.8 ± 0.5 |
1 : 0.12 | 5.3 ± 1.9 | 1.1 ± 0.4 | 3.2 ± 1.0 | 2.3 ± 1.2 |
1 : 0.06 | 5.4 ± 2.4 | 1.4 ± 0.5 | 2.6 ± 1.1 | 3.9 ± 3.1 |
1 : 0.03 | 4.3 ± 1.7 | 1.4 ± 0.5 | 2.2 ± 0.2 | 2.1 ± 1.2 |
aPBMC from healthy individuals were used as responder cells towards BM-derived MSCs pretreated with IFN-γ and TNF-α (MSC-BM IFN-γ/TNF-α) or not (MSC-BM) as stimulating cells at various responder : stimulator (R : S) ratios. Similar experiments were performed with BM-derived MSCs committed to osteodifferentiation process and pretreated with IFN-γ and TNF-α (Os-MSC-BM IFN-γ/TNF-α) or not (Os-MSC-BM) as stimulating cells.
bData are mean ± s.e.m. of alloproliferation percentage obtained with 5 and 3 distinct healthy donors for MSC-BM and Os-MSC-BM experiments, respectively. This percentage is calculated considering PBMC stimulated with LCL* as 100% alloproliferation.